Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 5/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203824 | 0.87 | CYP1A2 (0.67) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL20204022 | 0.85 | CYP1A2 (0.69) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL20203801 | 0.84 | CYP1A2 (0.67) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL20191119 | 0.83 | CYP1A2 (1.00) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL20189734 | 0.82 | CYP1A2 (0.61) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL23571890 | 0.81 | CYP1A2 (0.69) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL23571203 | 0.80 | CYP1A2 (0.57) | CYP1A2ADORA3ABL1SCN10ABCR | |
| SCHEMBL20190030 | 0.79 | CYP1A2 (0.63) | CYP1A2ADORA3ABL1DYRK1A | |
| SCHEMBL20189843 | 0.78 | CYP1A2 (0.61) | CYP1A2ADORA3ABL1 | |
| SCHEMBL20204049 | 0.78 | CYP1A2 (0.56) | CYP1A2ADORA3ABL1SCN10ABCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885ADORA3 2285/4885ABL1 3085/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885ADORA3 2285/4885ABL1 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.